Dishman Carbogen Amcis Share Price Today (DCAL)
TODAY IN ONE LINE
DCAL fell 2.5% on light volume, lagging Nifty's -0.8% move, supported by recent strong earnings.
With a market cap of ₹2,924.79 Cr., it trades at a P/E of 30.58. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Dishman Carbogen Amcis flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 19.3%
- ●High Promoter HoldingPromoters hold 59.3% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 49.5% YoY
- ●Poor Capital ReturnsLow ROE of 1.6%
- ●FII SellingFII holding decreased by 1.87% QoQ
- ●Rising Receivables vs SalesReceivables grew 37.3% outpacing sales growth of 3.7%
Latest Dishman Carbogen Amcis News
What changed recently?
Recent events, corporate actions, and announcements.
Dishman Carbogen Amcis Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Dishman Carbogen Amcis Limited, framed against the sector median so the premium or discount is obvious at a glance.
Dishman Carbogen Amcis Limited trades at a P/E of 30.58× and P/B of 0.45×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Dishman Carbogen Amcis Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Dishman Carbogen Amcis Limited — derived from the live tape, not yesterday's close.
Dishman Carbogen Amcis Limited last traded at ₹185.43 with an intraday range of ₹184.06–₹191.52 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹185.43| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 204.87 | +19.44 | +10.48% |
| R3 | 197.41 | +11.98 | +6.46% |
| R2 | 194.46 | +9.03 | +4.87% |
| R1 | 189.95 | +4.52 | +2.44% |
| PIVOT | 187.00 | 1.57 | 0.85% |
| CURRENT | 185.43 | — | — |
| S1 | 182.49 | -2.94 | -1.59% |
| S2 | 179.54 | -5.89 | -3.17% |
| S3 | 175.03 | -10.40 | -5.61% |
| S4 | 167.57 | -17.86 | -9.63% |
DCAL is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹186.73–₹191.52
Trading Below opening range, showing Bearishness
Dishman Carbogen Amcis Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Dishman Carbogen Amcis Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Dishman Carbogen Amcis Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,924.79 Cr. and reported EPS of ₹6.22.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 2,712 | 2,932 ▲ 8.1% |
| Sales Growth YoY %Derived | 3.66% | 8.13% |
| Other Income | 22 | 56 ▲ 158.0% |
| Total Income | 2,733 | 2,988 ▲ 9.3% |
| 502 | 409 ▼ 18.5% | |
| Gross ProfitDerived | 2,210 | 2,523 ▲ 14.2% |
| Gross Margin %Derived | 81.50% | 86.06% |
| 1,741 | 1,957 ▲ 12.4% | |
| EBITDA (Operating Profit)Derived | 469 | 566 ▲ 20.6% |
| OPM %Derived | 17.29% | 19.29% |
| 435 | 509 ▲ 17.0% | |
| Profit Before Tax (PBT) | 19 | 105 ▲ 443.2% |
| 16 | 7 ▼ 53.6% | |
| Effective Tax %Derived | 83.22% | 7.10% |
| Total Profit for Period | 3 | 97 ▲ 2907.7% |
| Net Profit (Owner's PAT)Derived | 3 | 97 ▲ 2907.7% |
| Net Profit Margin %Derived | 0.12% | 3.32% |
| PAT Growth YoY %Derived | 102.11% | 2,907.72% |
| Earnings Per Share (EPS ₹) | 0.21 | 6.22 ▲ 2861.9% |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 201 | 748 ▲ 272.5% |
| Total Expenses (incl. D&A & Interest) | 2,714 | 2,883 ▲ 6.2% |
| Material Cost % of RevenueDerived | 21.87% | 16.64% |
| Employee Cost % of RevenueDerived | 47.71% | 49.35% |
| Other Cost % of RevenueDerived | 16.50% | 17.41% |
| Interest Coverage (x)Derived | 1.10x | 1.30x |
| Period | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,695 | 1,695 ▲ 0.0% | 2,059 ▲ 21.5% | 2,044 ▼ 0.7% | 1,912 ▼ 6.4% | 2,141 ▲ 12.0% | 2,413 ▲ 12.7% | 2,616 ▲ 8.4% | 2,712 ▲ 3.7% | 2,932 ▲ 8.1% | |
| Sales Growth YoY %Derived | — | — | 21.47% | -0.73% | -6.44% | 11.96% | 12.72% | 8.41% | 3.66% | 8.13% | |
| Other Income | 46 | 46 ▲ 0.0% | 54 ▲ 17.8% | 44 ▼ 17.4% | 38 ▼ 13.5% | 43 ▲ 12.9% | 28 ▼ 36.0% | 28 ▲ 1.6% | 22 ▼ 23.1% | 56 ▲ 158.0% | |
| Total Income | 1,740 | 1,740 ▲ 0.0% | 2,112 ▲ 21.4% | 2,088 ▼ 1.2% | 1,950 ▼ 6.6% | 2,184 ▲ 12.0% | 2,441 ▲ 11.7% | 2,644 ▲ 8.3% | 2,733 ▲ 3.4% | 2,988 ▲ 9.3% | |
337 | 337 ▲ 0.0% | 404 ▲ 19.8% | 434 ▲ 7.4% | 468 ▲ 7.9% | 447 ▼ 4.4% | 511 ▲ 14.3% | 597 ▲ 16.8% | 502 ▼ 16.0% | 409 ▼ 18.5% | ||
| Gross ProfitDerived | 1,358 | 1,358 ▲ 0.0% | 1,655 ▲ 21.9% | 1,610 ▼ 2.7% | 1,444 ▼ 10.3% | 1,693 ▲ 17.3% | 1,902 ▲ 12.3% | 2,019 ▲ 6.2% | 2,210 ▲ 9.5% | 2,523 ▲ 14.2% | |
| Gross Margin %Derived | 80.12% | 80.12% | 80.39% | 78.77% | 75.52% | 79.10% | 78.81% | 77.17% | 81.50% | 86.06% | |
913 | 913 ▲ 0.0% | 1,103 ▲ 20.9% | 1,087 ▼ 1.4% | 1,170 ▲ 7.6% | 1,362 ▲ 16.4% | 1,569 ▲ 15.2% | 1,732 ▲ 10.4% | 1,741 ▲ 0.5% | 1,957 ▲ 12.4% | ||
| EBITDA (Operating Profit)Derived | 445 | 445 ▲ 0.0% | 552 ▲ 23.9% | 522 ▼ 5.3% | 274 ▼ 47.5% | 331 ▲ 20.8% | 332 ▲ 0.3% | 287 ▼ 13.8% | 469 ▲ 63.7% | 566 ▲ 20.6% | |
| OPM %Derived | 26.28% | 26.28% | 26.81% | 25.56% | 14.35% | 15.48% | 13.77% | 10.95% | 17.29% | 19.29% | |
260 | 260 ▲ 0.0% | 297 ▲ 14.1% | 345 ▲ 16.1% | 333 ▼ 3.3% | 350 ▲ 4.9% | 318 ▼ 9.0% | 425 ▲ 33.4% | 435 ▲ 2.4% | 509 ▲ 17.0% | ||
| Profit Before Tax (PBT) | 231 | 231 ▲ 0.0% | 309 ▲ 33.8% | 222 ▼ 28.1% | -65 ▼ 129.3% | -4 ▲ 93.5% | -55 ▼ 1184.5% | -122 ▼ 124.0% | 19 ▲ 115.8% | 105 ▲ 443.2% | |
76 | 76 ▲ 0.0% | 98 ▲ 29.2% | 42 ▼ 57.6% | 100 ▲ 139.6% | -22 ▼ 122.2% | -25 ▼ 11.4% | 31 ▲ 225.8% | 16 ▼ 48.5% | 7 ▼ 53.6% | ||
| Effective Tax %Derived | 33.03% | 33.03% | 31.89% | 18.81% | -153.93% | 523.76% | 45.41% | -25.51% | 83.22% | 7.10% | |
| Total Profit for Period | 155 | 155 ▲ 0.0% | 210 ▲ 36.1% | 180 ▼ 14.3% | -165 ▼ 191.6% | 18 ▲ 110.9% | -30 ▼ 265.5% | -153 ▼ 414.9% | 3 ▲ 102.1% | 97 ▲ 2907.7% | |
| Net Profit (Owner's PAT)Derived | 155 | 155 ▲ 0.0% | 210 ▲ 36.1% | 180 ▼ 14.3% | -165 ▼ 191.6% | 18 ▲ 110.9% | -30 ▼ 265.5% | -153 ▼ 414.9% | 3 ▲ 102.1% | 97 ▲ 2907.7% | |
| Net Profit Margin %Derived | 9.12% | 9.12% | 10.22% | 8.82% | -8.64% | 0.84% | -1.24% | -5.87% | 0.12% | 3.32% | |
| PAT Growth YoY %Derived | — | — | 36.07% | -14.28% | -191.59% | 110.91% | -265.46% | -414.93% | 102.11% | 2,907.72% | |
| Earnings Per Share (EPS ₹) | 9.58 | 9.58 ▲ 0.0% | 13.03 ▲ 36.0% | 11.49 ▼ 11.8% | -10.53 ▼ 191.6% | 1.15 ▲ 110.9% | -1.90 ▼ 265.2% | -9.79 ▼ 415.3% | 0.21 ▲ 102.1% | 6.22 ▲ 2861.9% | |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▼ 2.8% | 16 ▼ 0.1% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 292 | 292 ▲ 0.0% | 49 ▼ 83.2% | 211 ▲ 329.6% | 130 ▼ 38.4% | -164 ▼ 226.4% | 291 ▲ 276.9% | -29 ▼ 109.9% | 201 ▲ 798.3% | 748 ▲ 272.5% | |
| Total Expenses (incl. D&A & Interest) | 1,510 | 1,510 ▲ 0.0% | 1,804 ▲ 19.5% | 1,866 ▲ 3.5% | 2,016 ▲ 8.0% | 2,188 ▲ 8.6% | 2,495 ▲ 14.0% | 2,766 ▲ 10.9% | 2,714 ▼ 1.9% | 2,883 ▲ 6.2% | |
| Material Cost % of RevenueDerived | 23.07% | 23.07% | 18.36% | 22.73% | 22.06% | 21.51% | 25.90% | 22.98% | 21.87% | 16.64% | |
| Employee Cost % of RevenueDerived | 36.90% | 36.90% | 34.71% | 37.30% | 45.65% | 45.85% | 42.91% | 46.19% | 47.71% | 49.35% | |
| Other Cost % of RevenueDerived | 16.94% | 16.94% | 18.86% | 15.91% | 15.51% | 17.77% | 22.13% | 20.03% | 16.50% | 17.41% | |
| Interest Coverage (x)Derived | 4.79x | 4.79x | 5.51x | 3.87x | -0.71x | 0.42x | 0.60x | -0.20x | 1.10x | 1.30x |
Dishman Carbogen Amcis segment analysis : revenue and profit mix.
Disclosed business segments at Dishman Carbogen Amcis with their share of revenue and profit, switchable between consolidated and standalone reporting.
Dishman Carbogen Amcis discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Dishman Carbogen Amcis Limited.
Our AI distills the core fundamental drivers supporting Dishman Carbogen Amcis Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Dishman Carbogen Amcis Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding of 59.32% ensures aligned long-term governance and strategic direction.
TTM revenue grew 18.9% YoY, outpacing peer median growth in pharmaceutical sector.
Operating margin of 7.74% TTM demonstrates reasonable cost control despite competitive pressures.
Net operating cash flow positive at ₹295.23 Cr (latest quarter), improving liquidity position.
FII holdings increased from 5.85% to 8.07%, signaling growing international investor confidence.
Key Risks.
Latest quarterly EPS declined 49.5% YoY, indicating severe earnings volatility and profitability stress.
ROE of 1.58% and ROCE of 3.15% far below sector averages, reflecting poor capital efficiency.
Total debt ₹2,389 Cr with D/E 0.46x creates significant solvency and refinancing risk.
Zero dividend yield and no dividend payout limits income appeal for yield-seeking investors.
Net profit margin compressed to 2.51% TTM, down from 3.32% annually, signaling margin erosion.
Flip Conditions.
Valuation risk. a P/E above 40 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Dishman Carbogen Amcis Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Dishman Carbogen Amcis Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Dishman Carbogen Amcis Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Dishman Carbogen Amcis Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Dishman Carbogen Amcis Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Dishman Carbogen Amcis Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Dishman Carbogen Amcis Limited stood at 51.9% of traded volume, against a 20-day average of 48.3%.
Dishman Carbogen Amcis announcements: results, concalls, ratings, M&A.
Filings Dishman Carbogen Amcis sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Dishman Carbogen Amcis files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 115 documents below.
Copy of Newspaper Publication
Dishman Carbogen Amcis Limited has informed the Exchange about Copy of Newspaper Publication
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Dishman Carbogen Amcis Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Disclosure under SEBI Takeover Regulations
Adimans Technologies LLP has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Press Release
Dishman Carbogen Amcis Limited has informed the Exchange regarding a press release dated Jun 29, 2026, titled "PRESS RELEASE REGARDING COMPANY S…
Copy of Newspaper Publication
Dishman Carbogen Amcis Limited has informed the Exchange about Copy of Newspaper Publication regarding intimation of EGM of the Company to be held on…
Investor decks & rating reports.
Dishman Carbogen Amcis dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Dishman Carbogen Amcis has declared, sequenced by announce and record date.
Dishman Carbogen Amcis corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Dishman Carbogen Amcis Limited: business, sector, key facts.
What Dishman Carbogen Amcis Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Dishman Carbogen Amcis Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: DCAL, BSE: 540701.
Dishman Carbogen Amcis Limited (DCAL) is a global contract research and manufacturing services (CRAMS) provider catering to the pharmaceutical, healthcare, and biotechnology sectors. Their core business revolves around offering comprehensive services throughout the drug development and manufacturing lifecycle, from research and development to the production of finished products. This broad scope allows them to partner with clients across various stages of drug development and commercialization.
The company's operations are primarily structured around two segments: Contract Research and Manufacturing Services and Marketable Molecules. The CRAMS segment focuses on providing customized solutions for clients' research and manufacturing needs, encompassing a wide range of services tailored to specific client requirements. This includes everything from the initial stages of drug discovery and development to large-scale manufacturing of pharmaceutical products.
The Marketable Molecules segment involves the manufacturing and supply of various pharmaceutical and related products. This segment includes a diverse portfolio of offerings, ranging from bulk drugs and active pharmaceutical ingredients (APIs), including both general and highly potent APIs, to specialty chemicals used in pharmaceutical and cosmetic applications. Specific examples of their manufactured products include intermediates, fine chemicals, phosphoranes, solid quaternary ammonium compounds, and Wittig reagents.
Beyond these core offerings, DCAL also produces a range of other products. This diversification further strengthens their market position and demonstrates their commitment to providing a wide array of solutions to their clients. Their product portfolio extends to vitamin D products and analogues, personal care items like hand and body wash, sanitizers, and antiseptics, and even phase transfer catalysts, soft gel capsules, disinfectant formulations, cholesterol-related products, lanolin-related products, and liquid and lyophilized sterile injectables.
Established in 1983 and headquartered in Ahmedabad, India, DCAL is a subsidiary of Adimans Technologies LLP. Their extensive product range and comprehensive service offerings position them as a significant player in the global pharmaceutical and healthcare industries, providing a valuable link in the chain from drug discovery to market delivery.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Dishman Carbogen Amcis Limited (DCAL).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Dishman Carbogen Amcis Limited (DCAL)?
The current share price of Dishman Carbogen Amcis Limited (DCAL) is ₹185.43. Today, the stock has declined by ₹4.76 (2.50%), trading in a range of ₹184.06 to ₹191.52. The stock opened at ₹189.9 with a trading volume of 1,21,231 shares.
02Is Dishman Carbogen Amcis Limited stock a good investment for long-term?
Dishman Carbogen Amcis Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,924.79 crores, P/E ratio of 30.58, ROE of 1.58%, and ROCE of 3.15%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Dishman Carbogen Amcis Limited stock?
The 52-week high price of Dishman Carbogen Amcis Limited (DCAL) is ₹321.95, while the 52-week low is ₹128.5. Currently trading at ₹185.43, the stock is 29.4% away from its 52-week low and 42.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Dishman Carbogen Amcis Limited stock at the current price?
Whether to buy Dishman Carbogen Amcis Limited stock at ₹185.43 depends on multiple factors. The stock is currently trading with a P/E ratio of 30.58 and P/B ratio of 0.45. Today's performance shows a loss of 2.50%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Dishman Carbogen Amcis Limited and when is the next dividend?
Dishman Carbogen Amcis Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹185.43, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Dishman Carbogen Amcis Limited?
Dishman Carbogen Amcis Limited's key financial metrics include: P/E Ratio: 30.58, P/B Ratio: 0.45, ROE: 1.58%, ROCE: 3.15%, Dividend Yield: 0.00%, EPS: ₹6.22, Book Value: ₹426.9, and Debt-to-Equity: 0.46. The company's market cap stands at ₹2,924.79 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Dishman Carbogen Amcis Limited stock performing today in the market?
Dishman Carbogen Amcis Limited stock opened at ₹189.9 and is currently trading at ₹185.43, showing a decline of ₹4.76 (2.50%). The intraday high is ₹191.52 and low is ₹184.06. The trading volume stands at 1,21,231 shares, indicating moderate market participation today.
08What is the P/E ratio of Dishman Carbogen Amcis Limited and what does it indicate?
Dishman Carbogen Amcis Limited has a Price-to-Earnings (P/E) ratio of 30.58, which means investors are willing to pay ₹30.58 for every ₹1 of earnings. With an EPS of ₹6.22, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Dishman Carbogen Amcis Limited (DCAL) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.